Ameet Nathwani

Ameet Nathwani is a highly accomplished professional with over 25 years of experience in the pharmaceutical and biotechnology industry.

Currently serving as the Chief Executive Officer at Dewpoint Therapeutics, Ameet is driven by a profound ambition to integrate cutting-edge biological science, advanced technologies, and sophisticated analytics for developing customized patient solutions for global diseases with unmet needs.

With a background in Medicine from Middlesex Hospital Medical School, Ameet has held prominent executive positions in renowned companies like Sanofi and Novartis, where he spearheaded crucial initiatives blending medical science and digital technologies to enhance patient outcomes.

During his tenure at Novartis, Ameet successfully led various global development programs, secured approvals for multiple products, and pioneered advancements in areas such as Digital Therapeutics and Real-World Evidence, with a focus on AI integration.

Ameet's expertise spans across multiple disciplines including soft matter physics, biophysical chemistry, pathology, and AI, which are crucial for the innovative approach being pursued at Dewpoint Therapeutics under his leadership.

His remarkable career achievements include establishing a pipeline of Digital Therapeutics, developing a cutting-edge Real-World Evidence platform, obtaining global approvals for numerous products, and leading 20 global development programs.

Ameet's vision is to discover unique targets that traditional methods might overlook, potentially revolutionizing the industry with breakthrough medicines across various therapeutic areas.